BTK (E41K)

BTK · Variant type: point · HGVS: p.E41K

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pirtobrutinib	99.4%	0.6%	99.49
2	Zanubrutinib	99.1%	0.9%	98.24
3	Bosutinib	99.0%	0.9%	87.22
4	Dasatinib	98.7%	1.3%	87.97
5	Neratinib	98.3%	1.7%	93.18
6	Mobocertinib	98.1%	1.9%	97.22
7	Ibrutinib	97.7%	2.4%	94.74
8	Entrectinib	97.4%	2.6%	93.69
9	Acalabrutinib	96.4%	3.6%	99.50
10	Remibrutinib	95.1%	4.9%	99.50
11	Nintedanib	93.7%	6.3%	90.23
12	Canertinib	93.4%	6.6%	96.49
13	Osimertinib	90.3%	9.7%	97.24
14	Futibatinib	82.3%	17.7%	98.48
15	Repotrectinib	77.9%	22.1%	84.21
16	Dacomitinib	75.9%	24.1%	97.99
17	Pacritinib	75.4%	24.6%	88.64
18	Ponatinib	74.4%	25.6%	78.23
19	Fostamatinib	64.0%	36.0%	96.74
20	Pemigatinib	63.3%	36.7%	98.23
21	Pralsetinib	58.4%	41.6%	93.43
22	Vandetanib	55.2%	44.8%	95.74
23	Brigatinib	54.3%	45.7%	82.96
24	Cabozantinib	53.1%	46.9%	92.73
25	Gilteritinib	43.0%	57.0%	88.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pirtobrutinib	99.4%	97.7%	+1.7%
Zanubrutinib	99.1%	97.4%	+1.7%
Bosutinib	99.0%	99.3%	-0.3%
Dasatinib	98.7%	99.3%	-0.6%
Neratinib	98.3%	93.9%	+4.4%
Mobocertinib	98.1%	97.4%	+0.8%
Ibrutinib	97.7%	98.8%	-1.1%
Entrectinib	97.4%	95.1%	+2.3%
Acalabrutinib	96.4%	95.9%	+0.6%
Remibrutinib	95.1%	97.7%	-2.6%
Nintedanib	93.7%	98.0%	-4.3%
Canertinib	93.4%	99.3%	-5.8%
Osimertinib	90.3%	96.3%	-6.0%
Futibatinib	82.3%	—	—
Repotrectinib	77.9%	93.7%	-15.8%
Dacomitinib	75.9%	87.2%	-11.3%
Pacritinib	75.4%	80.3%	-4.9%
Ponatinib	74.4%	—	—
Fostamatinib	64.0%	81.5%	-17.5%
Pemigatinib	63.3%	—	—
Pralsetinib	58.4%	—	—
Vandetanib	55.2%	83.8%	-28.5%
Brigatinib	54.3%	—	—
Cabozantinib	53.1%	—	—
Gilteritinib	43.0%	87.6%	-44.5%

Cancer	Organ	Source
chronic_lymphocytic_leukemia	Blood/Lymphatic System	ref
anaplastic_large_cell_lymphoma	Blood/Lymphatic System	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.1ms